Clinical validation of using a commercial synthetic-computed tomography solution for brain MRI-only radiotherapy treatment planning
Background and purpose: MRI-only radiotherapy treatment planning (RTP) relies on synthetic-CT (sCT) images for dose calculation. This study evaluates the clinical feasibility of using a commercial sCT solution in brain RTP, MRCAT Brain, focusing on dosimetric accuracy and patient setup verification....
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-09-01
|
| Series: | Technical Innovations & Patient Support in Radiation Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405632425000290 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849226968379162624 |
|---|---|
| author | Lamyaa Aljaafari Richard Speight David L. Buckley David Bird Bashar Al-Qaisieh |
| author_facet | Lamyaa Aljaafari Richard Speight David L. Buckley David Bird Bashar Al-Qaisieh |
| author_sort | Lamyaa Aljaafari |
| collection | DOAJ |
| description | Background and purpose: MRI-only radiotherapy treatment planning (RTP) relies on synthetic-CT (sCT) images for dose calculation. This study evaluates the clinical feasibility of using a commercial sCT solution in brain RTP, MRCAT Brain, focusing on dosimetric accuracy and patient setup verification. Method and materials: For dosimetric evaluation, 93 patients with brain cancer who were treated with volumetric modulated arc therapy (VMAT) using a CT/MRI fusion workflow were included. sCT images were generated using MRCAT Brain. The sCT images were rigidly co-registered to the CT images. The clinical plan produced on the CT was recalculated on the sCT. Dosimetric accuracy was assessed by comparing dose differences in dose volume histogram (DVH) statistics for the planning target volume (PTV) and organs at risk (OARs).For patient setup verification, 70 patients were included, and total of 572 cone beam CT (CBCT) registrations were performed with sCT and CT as reference images. The sCT matching accuracy was validated by comparing the translational and rotational differences between sCT-CBCT and CT-CBCT registrations. Results: The PTV mean dose difference between CT and sCT were 0.3 %, 0.4 %, and 0.2 % for D50%, D2%, and D98%, respectively. The OAR mean dose differences were less than 0.3 % for all OARs. 4 of 93 patients (4.3 %) showed gross dosimetric errors of greater than ± 2 %. 3/4 were caused by sCT error. For positioning verification, all results were between ± 1 mm and ± 1°. Conclusion: This study demonstrates the clinical feasibility of the MRCAT solution for brain MRI-only RTP, with dosimetric differences being clinically acceptable, along with submillimetre and sub-degree accuracy in patient setup verification. |
| format | Article |
| id | doaj-art-dd504cf4e50744809f78a3dd4cd7000f |
| institution | Kabale University |
| issn | 2405-6324 |
| language | English |
| publishDate | 2025-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Technical Innovations & Patient Support in Radiation Oncology |
| spelling | doaj-art-dd504cf4e50744809f78a3dd4cd7000f2025-08-24T05:13:30ZengElsevierTechnical Innovations & Patient Support in Radiation Oncology2405-63242025-09-013510032810.1016/j.tipsro.2025.100328Clinical validation of using a commercial synthetic-computed tomography solution for brain MRI-only radiotherapy treatment planningLamyaa Aljaafari0Richard Speight1David L. Buckley2David Bird3Bashar Al-Qaisieh4Leeds Institute of Cardiovascular & Metabolic Medicine (LICAMM), University of Leeds, Woodhouse, Leeds LS2 9JT, United Kingdom; Department of Medical Physics and Engineering, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, United Kingdom; King Saud bin Abdulaziz University for Health Sciences, Department of Diagnostic Radiology Faculty of Applied Medical Sciences, Alahssa, Saudi Arabia; Corresponding author at: Leeds Institute of Cardiovascular & Metabolic Medicine (LICAMM), University of Leeds, Woodhouse, Leeds, LS2 9JT, United KingdomDepartment of Medical Physics and Engineering, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, United Kingdom; Leeds Institute of Medical Research (LIMR), Wellcome Trust Brenner Building, St. James’s University Hospital, Beckett Street, Leeds LS9 7TF, United KingdomLeeds Institute of Cardiovascular & Metabolic Medicine (LICAMM), University of Leeds, Woodhouse, Leeds LS2 9JT, United KingdomDepartment of Medical Physics and Engineering, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, United Kingdom; Leeds Institute of Medical Research (LIMR), Wellcome Trust Brenner Building, St. James’s University Hospital, Beckett Street, Leeds LS9 7TF, United KingdomDepartment of Medical Physics and Engineering, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, United KingdomBackground and purpose: MRI-only radiotherapy treatment planning (RTP) relies on synthetic-CT (sCT) images for dose calculation. This study evaluates the clinical feasibility of using a commercial sCT solution in brain RTP, MRCAT Brain, focusing on dosimetric accuracy and patient setup verification. Method and materials: For dosimetric evaluation, 93 patients with brain cancer who were treated with volumetric modulated arc therapy (VMAT) using a CT/MRI fusion workflow were included. sCT images were generated using MRCAT Brain. The sCT images were rigidly co-registered to the CT images. The clinical plan produced on the CT was recalculated on the sCT. Dosimetric accuracy was assessed by comparing dose differences in dose volume histogram (DVH) statistics for the planning target volume (PTV) and organs at risk (OARs).For patient setup verification, 70 patients were included, and total of 572 cone beam CT (CBCT) registrations were performed with sCT and CT as reference images. The sCT matching accuracy was validated by comparing the translational and rotational differences between sCT-CBCT and CT-CBCT registrations. Results: The PTV mean dose difference between CT and sCT were 0.3 %, 0.4 %, and 0.2 % for D50%, D2%, and D98%, respectively. The OAR mean dose differences were less than 0.3 % for all OARs. 4 of 93 patients (4.3 %) showed gross dosimetric errors of greater than ± 2 %. 3/4 were caused by sCT error. For positioning verification, all results were between ± 1 mm and ± 1°. Conclusion: This study demonstrates the clinical feasibility of the MRCAT solution for brain MRI-only RTP, with dosimetric differences being clinically acceptable, along with submillimetre and sub-degree accuracy in patient setup verification.http://www.sciencedirect.com/science/article/pii/S2405632425000290MRI-only planningsynthetic-CT modelMRIBrainArtificial intelligence |
| spellingShingle | Lamyaa Aljaafari Richard Speight David L. Buckley David Bird Bashar Al-Qaisieh Clinical validation of using a commercial synthetic-computed tomography solution for brain MRI-only radiotherapy treatment planning Technical Innovations & Patient Support in Radiation Oncology MRI-only planning synthetic-CT model MRI Brain Artificial intelligence |
| title | Clinical validation of using a commercial synthetic-computed tomography solution for brain MRI-only radiotherapy treatment planning |
| title_full | Clinical validation of using a commercial synthetic-computed tomography solution for brain MRI-only radiotherapy treatment planning |
| title_fullStr | Clinical validation of using a commercial synthetic-computed tomography solution for brain MRI-only radiotherapy treatment planning |
| title_full_unstemmed | Clinical validation of using a commercial synthetic-computed tomography solution for brain MRI-only radiotherapy treatment planning |
| title_short | Clinical validation of using a commercial synthetic-computed tomography solution for brain MRI-only radiotherapy treatment planning |
| title_sort | clinical validation of using a commercial synthetic computed tomography solution for brain mri only radiotherapy treatment planning |
| topic | MRI-only planning synthetic-CT model MRI Brain Artificial intelligence |
| url | http://www.sciencedirect.com/science/article/pii/S2405632425000290 |
| work_keys_str_mv | AT lamyaaaljaafari clinicalvalidationofusingacommercialsyntheticcomputedtomographysolutionforbrainmrionlyradiotherapytreatmentplanning AT richardspeight clinicalvalidationofusingacommercialsyntheticcomputedtomographysolutionforbrainmrionlyradiotherapytreatmentplanning AT davidlbuckley clinicalvalidationofusingacommercialsyntheticcomputedtomographysolutionforbrainmrionlyradiotherapytreatmentplanning AT davidbird clinicalvalidationofusingacommercialsyntheticcomputedtomographysolutionforbrainmrionlyradiotherapytreatmentplanning AT basharalqaisieh clinicalvalidationofusingacommercialsyntheticcomputedtomographysolutionforbrainmrionlyradiotherapytreatmentplanning |